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C1q is the first recognition subcomponent of the complement classical pathway, which 
acts toward the clearance of pathogens and apoptotic cells. C1q is also known to mod-
ulate a range of functions of immune and non-immune cells, and has been shown to 
be involved in placental development and sensorial synaptic pruning. We have recently 
shown that C1q can promote tumor by encouraging their adhesion, migration, and pro-
liferation in addition to angiogenesis and metastasis. In this study, we have examined the 
role of human C1q in the microenvironment of malignant pleural mesothelioma (MPM), 
a rare form of cancer commonly associated with exposure to asbestos. We found that 
C1q was highly expressed in all MPM histotypes, particularly in epithelioid rather than in 
sarcomatoid histotype. C1q avidly bound high and low molecular weight hyaluronic acid 
(HA) via its globular domain. C1q bound to HA was able to induce adhesion and prolif-
eration of mesothelioma cells (MES) via enhancement of ERK1/2, SAPK/JNK, and p38 
phosphorylation; however, it did not activate the complement cascade. Consistent with 
the modular organization of the globular domain, we demonstrated that C1q may bind 
to HA through ghA module, whereas it may interact with human MES through the ghC. 
In conclusion, C1q highly expressed in MPM binds to HA and enhances the tumor 
growth promoting cell adhesion and proliferation. These data can help develop novel 
diagnostic markers and molecular targets for MPM.
Keywords: complement system, malignant pleural mesothelioma, hyaluronic acid, mesothelioma cells, c1q, 
cancer
Abbreviations: MPM, malignant pleural mesothelioma; MES, mesothelioma cells; ECM, extracellular matrix; HA, hyaluronic 
acid; ghA, ghB and ghC: globular head region of human C1q A, B and C chain, respectively; MBP, maltose-binding protein; 
HMW, high molecular weight; LMW, low molecular weight.
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inTrODUcTiOn
Malignant pleural mesothelioma (MPM) is a rare form of 
cancer that develops from cells of the pleural mesothelium 
and is most commonly associated with exposure to asbestos 
(1). MPM typically develops after a long latency period, which 
averages 30–40 years, and the average age of patients is 60 years 
(2). MPM is highly invasive to surrounding tissues leading to 
the failure of the organs underlying the serosal membranes (3). 
Although low in metastatic potential, metastasis in MPM are 
more frequent postsurgery; at the autopsy, metastatic diffusion 
is observed in 50% of patients (3). Microscopically, MPM shows 
mainly one of the three patterns: epithelioid, sarcomatoid, or 
biphasic (4).
MPM is an aggressive malignancy; most patients succumb 
within 2 years of being diagnosed (5). Treating MPM remains 
a challenge. There are two main treatment alternatives: pallia-
tive chemotherapy or multimodal treatment including surgical 
resection combined with chemotherapy or radiotherapy, or 
both (6). The resistance of MPM to conventional treatment and 
poor prognosis has renewed interest in basic research in order 
to understand the MPM biology fully with the aim of identify-
ing possible new molecular therapeutic targets.
The local microenvironment, which encourages survival, 
growth, and invasion of cancer cells, plays a critical role in 
cancer development; the extracellular matrix (ECM) is an 
essential constituent of such microenvironment (7). Hyaluronic 
acid (HA), a member of the glycosaminoglycan family, is an 
abundant and ubiquitous component of the ECM (8). HA is a 
negatively charged high-molecular-weight (HMW) polysaccha-
ride (4–800 kDa) which is made up of the repeating disaccharide 
(glucuronic acid and N-acetylglucosamine) (9). In the tumor 
microenvironment, HA offers a molecular 3D-scaffold for cells 
via the assembly of ECM, thus modulating stromal as well as 
tumor cells (10). HA, whose multiple functions are dictated by 
its molecular size and tissue concentration, relies on balanced 
biosynthetic and degradation processes. Increased HA synthesis 
has been associated with cancer progression and metastasis (11). 
In patients with MPM, large quantities of HA are found in the 
tumor tissue although both malignant and benign mesothelial 
cells have been found positive for intracytoplasmic HA (12).
The complement system also constitutes the local environ-
ment for cancer as an immune surveillance against malignant 
cells due to its ability to promote inflammation and causes direct 
cell killing (13). We focused our investigation on C1q, which is 
the first recognition subcomponent of the complement classi-
cal pathway. C1q is a potent link between innate and adaptive 
immunity by virtue of its ability to bind IgG- and IgM-containing 
immune complexes (14). In addition to being involved in the 
clearance of apoptotic cells, and thus maintenance of immune 
tolerance, C1q also has the ability to directly impact upon cell 
differentiation and proliferation, dendritic cell maturation, and 
synaptic pruning; functions that are not reliant on comple-
ment activation by C1q (15). Recently, involvement of C1q in 
pregnancy via its ability to modulate the endovascular (16) and 
interstitial invasion (17) of trophoblast cells in placenta has 
also been demonstrated. In addition, we have recently showed 
that C1q is present in several solid human tumor tissues and 
is involved in tumor progression (18).
The present study focused on the involvement of C1q in the 
proliferation and invasiveness of MPM. We found that C1q can 
bind to HA and acquires protumorigenic properties, leading 
to heightened adhesion, migration and proliferation of human 
mesothelioma cells (MES).
MaTerials anD MeThODs
reagent and antibodies
Hyaluronic acid was a kind gift from Prof. Ivan Donati, 
Department of Life Sciences, University of Trieste (19). C1q was 
either purified from fresh human serum following the procedure 
as described previously (20) or bought from Sigma-Aldrich 
(Milan, Italy). The recombinant globular head regions of the A, 
B, and C chains (ghA, ghB, and ghC, respectively) were expressed 
as fusion proteins linked to maltose-binding protein (MBP) in 
Escherichia coli BL21 and purified, as described previously (21). 
Poly-l-lysine, bovine serum albumin (BSA) and all reagents were 
from Sigma-Aldrich. The following antibodies were used: mono-
clonal antibody (mAb) mouse anti-human C1q was from Quidel 
(Quidel Corporation, San Diego, CA, USA), sheep anti-human 
C1q and anti-human C4 were purchased from The Binding Site 
(Bergamo, Italy). Mouse Monoclonal anti-C5b-9 antibody (aE11) 
was from AbCam. Mouse mAb anti-human von Willebrand fac-
tor (vWF), mouse mAb anti-human CD68, rabbit anti-human 
C1q, and goat anti-mouse-FITC F(ab)′ were purchased from 
Dako (Milan, Italy). Mouse mAb anti-human CD44-PE, mouse 
mAb anti-human CD45-PE-, or FITC-conjugated, unrelated 
mouse IgG1-PE- and FITC-conjugated were from Immunotools 
(Friesoythe, Germany). Cy3-conjugated F(ab′)2 goat anti-mouse 
IgG, and FITC-conjugated F(ab′)2 goat anti-rabbit IgG. Mouse 
mAb anti-human Mesothelin and rabbit anti-human Calretinin 
were from Santa Cruz Biotechnology (DBA, Milan, Italy). Mouse 
monoclonal anti-human Vimentin, goat anti-mouse IgG alkaline 
phosphatase (AP)-conjugated, anti-rabbit IgG-AP-conjugated, 
and anti-goat IgG-AP-conjugated were from Sigma-Aldrich.
Patients and specimens
MPM patients who were diagnosed and followed up at the 
Department of Pneumology, University Hospital of Cattinara, 
Trieste, Italy, were enrolled for this study. None of the patients 
received chemotherapy or radiotherapy prior to sampling.
Patients (five male) with reported asbestos exposure under-
went pleuroscopy for diagnosis of pleural effusion. All the pro-
cedures were performed under conscious sedation achieved by 
titration of intravenous midazolam and meperidine. Before the 
procedure, patients were placed in the lateral decubitus posi-
tion with the pleural effusion uppermost and a bedside chest 
ultrasonography was used to determine the entry site. After the 
creation of the sterile field and injection of 2% lidocaine in the 
intercostal space in order to obtain local anesthesia, a 2-cm skin 
incision was made with a scalpel, then blunt dissection of the 
chest wall was performed using curved Kelly forceps down to 
the parietal pleural. Finally, a trocar was placed into the pleural 
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space and the pleuroscope (Karl Storz GmbH, Tuttlingen, 
Germany) was inserted to examine parietal and visceral pleura 
to obtain parietal pleural specimens using dedicated forceps. 
At the end of the procedure, pleuroscope and trocar were 
removed and a chest tube was inserted trough the chest wall.
Tissue samples from patients were collected after informed 
consent following approval of the ethical considerations by the 
Institutional Board of the University Hospital of Trieste, Italy.
cell isolation and culture
Mesothelioma cells were isolated from pleural biopsy specimens. 
The tissue was finely minced with a cutter, incubated with a diges-
tion solution composed of 0.5% trypsin (Sigma-Aldrich, Milan, 
Italy) and 50  µg/ml DNase I (Roche, Milan, Italy) in Hanks’ 
Balanced Salt solution with Ca2+Mg2+ 0.5 mM (Sigma-Aldrich) 
overnight at 4°C. Next, the enzymatic solution was replaced 
with collagenase type 1 (3  mg/ml) (Worthington Biochemical 
Corporation, DBA) diluted in Medium 199 with Hank’s salts 
(Euroclone Spa, Milan, Italy) for 30 min at 37°C. The digestion 
was blocked with 10% fetal bovine serum (FBS, GIBCO, Life 
Technology) and the cell suspension was filtered through a 
100 µm pore filter (BD Biosciences, Italy).
The cells were seeded in a 12.5 cm2 flask and cultured using 
Roswell Park Memorial Institute (RPMI) medium 1640 with 
GlutaMAX (Life Technologies, Milan, Italy), 45% human 
endothelial cells serum-free medium (HESF, Life Technologies), 
10% heat-inactivated FBS supplemented with EGF (5  ng/ml), 
basic FGF (10  ng/ml), and penicillin–streptomycin (Sigma-
Aldrich). Fresh medium was replaced every 2–3 days. MES were 
used at their five to eight passages for all the in vitro experiments.
Met5A cells were purchased from ATCC. These cells were 
grown in DMEM supplemented with 10% FBS and 1% antibiotic 
mixture (Sigma-Aldrich) and maintained at 37°C in humidified 
atmosphere with 5% CO2.
Pleural effusions
Malignant pleural effusions (MPEs) were obtained from patients 
who underwent thoracentesis after diagnosis of MPM in order 
to remove the exudative liquid filling pleural space. The surgery 
was performed within the Department of Pathologic Anatomy 
of the Hospital of Monfalcone (Gorizia, Italy). MPEs were 
immediately stored at 4°C for a maximum of 24 h before being 
processed. Approximately 1 Liter of MPE was centrifuged twice 
at 250 g for 10 min to remove the cells.
Dose-Determination of soluble c1q
A 96-well plate (Corning Costar) was coated with sheep anti-
C1q (1:6.000) diluted in carbonate/bicarbonate buffer (100 mM, 
pH  >  9) and incubated overnight at 4°C. In order to avoid 
non-specific binding, the microtite wells were blocked with 
2% skimmed milk (SM) in PBS and incubated for 2 h at 37°C. 
In the meanwhile, samples to be dose-titrated were prepared 
and then added to the wells in triplicate. A standard curve was 
prepared using a serial dilution of purified C1q (Sigma-Aldrich) 
from 50 to 1.56 ng/ml and the plate was incubated overnight at 
4°C. Rabbit anti-human C1q (1:1,000) diluted in PBS +  0.5% 
SM + 0.05% Tween was incubated for 1 h at 37°C, followed by 
secondary probing with anti-rabbit IgG-alkaline phosphatase 
(AP) conjugate (1:20,000) for 30  min at 37°C. p-nitrophenyl 
phosphate (pNPP) was used as substrate, as described above, and 
the developed color was measured at 405 nm using the Titertek 
Multiskan ELISA Reader (Flow Labs).
immunohistochemical analysis
Tissue samples of different MPM histotypes were fixed in 10% 
buffered formalin and paraffin embedded. Sections of 4 µm in 
thickness were fixed with xylene, 100% EtOH, and 95% EtOH and 
then microwaved three times in Tris–HCl/EDTA pH 9.0 buffer 
(Dako, Milan, Italy) for 5 min and washed in Tris-buffered saline. 
After neutralization of the endogenous peroxidase with H2O2 
(hydrogen peroxide) for 10 min, the sections were first incubated 
with PBS + 2% w/v BSA + 0.4% w/v Casein for 5 min in order 
to block the non-specific sites, and then probed with rabbit anti-
human C1q (1:500) overnight at 4°C. The bound antibodies were 
revealed using the Vectastain Elite ABC horseradish peroxidase 
(HRP) kit (Vector Laboratories, DBA, Italy). Secondary antibod-
ies were detected by 3-amino-9-ethylcarbazole (AEC) +  high 
sensitivity Chromogen (Dako). The sections were counterstained 
with hematoxylin (Dako). Slides were examined under a Leica 
DM 3000 optical microscope and images were collected using 
a Leica DFC320 digital camera (Leica Microsystems, Wetzlar, 
Germany).
alcian Blue staining
After deparaffinizing and rehydrating, the sections were incu-
bated with a solution of 1% Alcian blue dissolved in 3% Acetic 
acid, pH 2.5, for 30 min at RT. After washing in tap water for 
10 min, the sections were dehydrated well in absolute alcohol and 
mounted. Images were acquired by the fluorescence microscope 
Leica DM 3000 using the Leica DFC320 camera.
immunofluorescence Microscopy of Mes
Mesothelioma cells cultured at confluence in an eight-chamber 
slide (BD Falcon) were fixed with FIX&PERM kit (Invitrogen, 
Life Technologies) for 15  min at RT. Incubation with primary 
antibodies (as listed earlier) was carried out for 1 h at RT. Cells 
were then washed and incubated with corresponding secondary 
antibodies (1:300) for 45  min at RT. The nuclei were stained 
with DAPI (Sigma-Aldrich). The glass was mounted with the 
Fluorescence Mounting Medium (Dako) and covered with a 
cover slip. Images were acquired by the fluorescence microscope 
Leica DM 3000 using the Leica DFC320 camera.
Flow cytometry
Mesothelioma cells (5 × 105) were fixed with the fixation reagent 
FIX&PERM kit for 15 min at RT in dark and incubated with pri-
mary antibodies for 1 h at 37°C in a thermomixer (Eppendorf) at 
800 rpm. Antibodies directed against intracellular antigens were 
diluted in permeabilization reagent of the FIX&PERM kit, while 
antibodies for cell surface antigens were diluted in PBS-1% w/v 
BSA. Incubation with secondary antibodies anti-mouse-FITC 
F(ab)′ (1:50) or anti-rabbit-FITC (1:300) was performed for 
30 min on ice. Cells were suspended in 1% paraformaldehyde, the 
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fluorescence was acquired with the FACScalibur (BD Bioscience), 
and data processed using the software CellQuest.
Binding of c1q to Mes
Mesothelioma cells were grown to confluence in 96-well tissue 
culture plates and incubated directly with increasing concentra-
tions of purified human C1q or preincubated with increasing 
concentrations of HA, for 1 h at room temperature. Bound C1q 
was revealed by ELISA using mAb anti-human C1q (10 µl/ml) 
and alkaline-phosphatase-conjugated secondary antibodies 
(Sigma-Aldrich). The color, developed using pNPP (Sigma-
Aldrich; 1  mg/ml) as a substrate, was read at 405  nm using a 
Titertek Multiskan ELISA reader (Flow Labs, Milano, Italy).
coating conditions
The microtiter wells were coated overnight at 4°C with HMW HA 
(50 µg/ml), C1q (20 µg/ml), ghA, ghB, ghC, or BSA (as a negative 
control; Sigma-Aldrich) diluted in 100  mM carbonate/bicarbo-
nate buffer, pH 9.6. C1q was allowed to bind (25 µg/ml) to HA 
in PBS + 0.5% BSA, 0.7 mM CaCl2, and 0.7 mM MgCl2, overnight 
at 4°C.
adhesion assay
1 ×  105 mesothelial cells or MES, labeled with the fluorescent 
dye FAST DiI (Molecular Probes, Invitrogen), were re-suspended 
in HESF (Life Technologies) containing 0.1% BSA (HESF + 0.1% 
BSA; Sigma), preincubated with 10  µM of ERK (#SCH772984, 
Selleckchem), JNK (#SP600125, SIGMA-Aldrich), or p38 
(#SB203580, Selleckchem) inhibitors for 30 min at RT and then 
added to a 96-well plate (wells were coated as described above) for 
35 min at 37°C in 5% v/v CO2 incubator. Then, the unbound cells 
were removed and the adherent cells were lysed with 10 mM Tris–
HCl, pH 7.4 + 0.1% v/v SDS. The plate was read via Infinite200 
(544 nm, emission 590 nm) (TECAN) using a calibration curve 
generated through an increasing number of labeled cells.
cell Proliferation
The cell proliferation assay was performed using Click-iT® Plus 
EdU Proliferation Kits (ThermoFisher). 5 ×  103 MES were re-
suspended in HESF + 0.1% BSA medium and seeded to a 96-well 
plate, which was earlier coated with C1q, HA or C1q + HA, as 
described above. Following adhesion, cells were incubated with 
15  µM analog EdU nucleotide (5-ethynyl-2-deoxyuridine) for 
DNA incorporation during replication. Cells were then incubated 
for 24 h at 37°C, fixed, and set up for a marking reaction by azide 
Oregon-Green 488. The signal amplification step included the 
incubation with antibody anti-Oregon-Green conjugated with 
HRP that reacts with the substrate, Amplx UtraRed, and pro-
duces a bright response that beams fluorescence around red. The 
fluorescence was analyzed by TECAN (Tecan, Milan, Italy) in the 
excitation/emission range of 535/595 nm.
apoptosis
Mesothelioma cells grown without serum, were suspended in 
0.1% w/v BSA in HEFS, and 2 × 104 cells/well were seeded on 
precoated plates. The cells were left to adhere for 1  h at 37°C, 
then incubated with 500  µM of H2O2 for 6  h, before adding 
5  µM of CellEvent™ Caspase-3/7 Green Detection Reagent 
(Life Technologies), a fluorogenic substrate for activated caspases 
3 and 7.
Migration assay
FAST DiI-labeled (Molecular Probes, Invitrogen, 1:100) MES 
(2 × 105 cells) were resuspended in 0.1% w/v BSA in HEFS and 
added to the upper chamber of a transwell system. The cells 
were allowed to migrate through HTS FluoroBlok systems with 
polycarbonate membranes of 8  µm pore size (Falcon) coated 
on the lower side, as described above. The plate was read using 
Infinite200, as described above.
scratch assay
Confluent monolayers of MES (2  ×  105) were seeded in 
HESF  +  0.1% BSA medium in 24-well plate. A scratch was 
placed in the middle of the well with a sterile 200 µl pipette tip. 
Subsequently, HA (50 µg/ml) or HA + C1q (20 µg/ml) were added 
to the wells. Cells incubated with 10% v/v FBS and as negative 
control MES were cultured in HESF/BSA (0.1%) medium with-
out stimuli. Images were acquired by phase-contrast microscope 
(Leica).
Phosphorylation of erK, saPK/JnK,  
and p38 in Mes
Pathway analysis was performed as per the manufacturer’s 
instructions of the PathScan® Intracellular Signaling Array 
Kit (Fluorescent Readout) (#7744; Cell Signaling Technology, 
EuroClone, Milan, Italy). Briefly, 24  h serum-starved MES 
(1.8 × 106 cells) were left to adhere to HA, or HA-bound-C1q, 
as described above for the indicated periods of time at 37°C. 
Then, the cells were washed with ice-cold 1× PBS and lysed 
in 1× ice-cold Cell Lysis buffer containing a cocktail of pro-
tease inhibitors (Roche Diagnostics). The Array Blocking 
Buffer was added to each well and incubated for 15 min at RT. 
Subsequently, an equal amount of total lysate (0.8 mg/ml) was 
added to each well and incubated for 2  h at RT. After wash-
ing, the biotinylated detection antibody cocktail was added to 
each well and incubated for 1 h at RT. Streptavidin-conjugated 
DyLight 680 was added to each well and incubated for 30 min 
at RT. Fluorescence readout was acquired using the LI-COR 
Biosciences Infrared Odyssey imaging system (Millennium 
science) and data processed by the software Image studio 5.0.
Detection of the interaction between 
human c1q (and its recombinant 
globular head Modules) and ha
The microtiter wells were coated overnight at 4°C with either 
50 µg/ml HA of different MWs diluted in carbonate/bicarbonate 
buffer (100 mM, pH 9.6). The blocking step with PBS + 1% BSA 
(2  h at 37°C) was followed by incubation with an increasing 
concentration of human C1q or the recombinant globular head 
modules (ghA, ghB, and ghC) of human C1q in PBS-Ca2+Mg2+ 
(0.7  mM) containing 0.5% BSA (PBS-CaMg-0.5% BSA) over-
night at 4°C. Bound C1q was detected with sheep anti-human 
C1q polyclonal antibodies whereas bound ghA, ghB, and ghC 
were detected with mouse anti-MBP (1 h at 37°C). The binding 
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of anti-C1q was detected using anti-goat IgG-AP conjugate, 
whereas the anti-MBP binding was detected using anti-mouse 
IgG-AP conjugate for 30 min at 37°C. The phosphatase substrate, 
pNPP (Sigma-Aldrich) was dissolved in 0.1 M glycine buffer con-
taining 1 mM MgCl2, 1 mM ZnCl2, pH 10.4 at a concentration of 
1.5  mg/ml. The absorbance was measured at 405  nm with the 
Titertek Multiskan ELISA Reader (Flow Labs).
evaluation of complement activation
Microtitre wells in a 96-well plate were coated with HA (50 µg/ml) 
or IgG (10 µg/ml), as described above. Non-specific binding sites 
were blocked with PBS-1%BSA for 1 h at 37°C, and then incu-
bated with 20 and 50 µg/ml C1q diluted in PBS-CaMg-0.5%BSA 
for 1  h at 37°C. Subsequently, the wells were incubated with 
pooled normal human serum (1:100) as a source of comple-
ment components in PBS-CaMg-0.5%BSA and incubated for 
30  min at 37°C with gentle shaking. C9 neoantigen detection 
was performed using the murine mAb aE11 against C9 neoan-
tigen (kindly provided by Prof. T. E. Mollnes, Oslo, Norway) 
and incubated for 1 h at 37°C. The AP-conjugated anti-goat IgG 
(Sigma-Aldrich) or anti-mouse IgG (Sigma-Aldrich), used as 
secondary antibodies, were incubated 30  min at 37°C. pNPP 
(Sigma) was dissolved in glycine buffer at the concentration of 
1.5 mg/ml. The absorbance was measured at 405 nm with the 
Titertek Multiskan ELISA Reader (Flow Labs).
statistical analysis
Data were analyzed using Two-way ANOVA, Tukey–Kramer 
test, and unpaired two-tailed Student’s t-test or one-way 
ANOVA with Bonferroni corrections. Results were expressed 
as mean ± SEM. Non-parametric data were assessed by Mann–
Whitney U tests and the results were expressed as median 
and interquartile range. p values <  0.05 were considered sig-
nificant. All statistical analyses were performed using Prism 6 
software (GraphPad Software Inc., La Jolla, CA, USA).
resUlTs
c1q is Present in Malignant Pleural 
Mesothelioma specimens
We initially looked for the presence of C1q in a panel of invasive 
MPM specimens, including epithelioid, biphasic, and sarco-
matoid (Figure 1A) histotypes. As shown in Figure 1, a strong 
positivity for C1q was detected in all tumor specimen types 
examined, particularly in epithelioid histotype.
Within the mesothelioma microenvironment, C1q was mainly 
expressed by monocytoid cells suggestive of tumor-infiltrating 
myeloid elements (shown by arrows in the upper panels) and 
in the small vessels, as indicated by the black triangles of the 
lower panels in Figure  1B. C1q was also diffusely present in 
the tumor stroma and associated with the cell membrane of 
tumor cells. Immunohistochemical controls of C1q are shown 
in Figure 2. The presence of C1q was also detected in the three 
pleural exudate by a quantitative ELISA assay. We found out 
that the concentration of C1q was found to be about 76 µg/ml 
(±8 μg/ml), approximately two- or threefold lower than our 
control serum (about 200 µg/ml).
Binding of c1q to ha does not activate  
the complement classical Pathway
Having shown that C1q is abundantly present in the mesothe-
lioma microenvironment, we investigated the ability of C1q to 
interact with ECM components. We focused our attention to HA 
which is abundantly present in mesothelioma tissue (22). The 
presence of HA is clearly evident in Figure  3, where we show 
sections obtained from epithelioid and a biphasic mesothelioma 
tissue stained with Alcian blue.
We previously demonstrated that C1q is able to bind to a 
range of target ligands present in the ECM; this interaction 
is particularly strong with HA (17). We confirmed by ELISA 
the ability of C1q to bind to HA in a manner similar to IgG 
(Figure  4A). We also analyzed the binding of C1q to HA of 
different molecular weights (Figure 4B). Our results indicated 
that there were no statistically significant differences in C1q 
binding to low and high MW-HA. Furthermore, we evaluated 
the capability of HA-bound C1q to activate the complement 
classical pathway, by measuring the C4 and C9 (neoantigen) (C9 
neo) deposition by ELISA. As shown in Figures 4C,D, only C1q 
bound to IgG, and not HA-bound C1q, induced complement 
activation, and therefore, C4 deposition and C9-neoantigen 
formation. In order to localize the C1q interaction with HA, 
we analyzed the binding of recombinant forms of individual 
globular head modules (ghA, ghB, and ghC) to HA. Our results 
indicated that the globular head of C1q A chain (ghA) bound 
to HA better than ghB and ghC (Figure 4E), suggesting a dif-
ferential and modular nature of the interaction between the 
gC1q domains and HA.
isolation and characterization of Primary 
Tumor cells from MPM Biopsies
Having established that C1q is present in the MPM microen-
vironment and that it can bind to HA, we sought to investigate 
the implication of its presence in MPM biology. Therefore, we 
isolated MES from a portion of the resected malignant pleura, 
obtained during diagnostic pleuroscopy, from five patients 
with epithelioid MPM. We compared the MES morphology 
with Met5A, a commercial, immortalized mesothelial cell line, 
commonly used as a model of healthy cells. MES had mainly 
an elongated and filamentous shape and were very heterogene-
ous and multishaped (Figure 5A). It is possible to notice that 
there are also some polygonal and more regular cells in culture, 
which seem to resemble the epithelial phenotype of Met5A. 
Generally, they had an abundant cytoplasm in which vacuoles 
or granules were often present, transforming themselves in 
signet-ring cells.
We characterized MES for the expression of typical mesothe-
lial markers, such as mesothelin, calretinin, CK8-18, and CD44 
by immunofluorescence microscopy. The cells were also positive 
for vimentin, a marker of mesenchymal cells (Figure 5B). MES 
were positive for the above-mentioned markers. To assess the 
FigUre 2 | Immunohistochemical controls for C1q. Representative microphotographs showing the immunohistochemistry controls: positive control tissue, lupus 
nephritis (a), scale bar, 100 µm; negative control tissue, pleural benign cyst (B), scale bar, 200 µm; negative control reaction, biphasic mesothelioma (c), scale bars, 
100 µm. Streptavidin–biotin–peroxidase complex system with 3-amino-9-ethylcarbazole (AEC) (red) chromogen.
FigUre 1 | Immunohistochemical analysis for C1q in human mesothelioma. (a) Representative microphotographs showing expression of C1q in different malignant 
pleural mesothelioma (MPM) histotypes: epithelioid (i), biphasic (ii), and desmoplastic (iii). Streptavidin–biotin–peroxidase complex system with 3-amino-9-
ethylcarbazole (AEC) (red) chromogen; scale bars, 50 µm. (B) Representative microphotographs showing the expression of C1q in tumor-associated stroma of 
mesothelioma. Highlighted are monocytoid cells suggestive of tumor-infiltrating myeloid elements (arrows) and neovascular endothelial cells (arrow heads). 
Streptavidin–biotin–peroxidase complex system with AEC (red) chromogen; scale bars, 100 µm.
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purity of isolated primary cells, we performed immunopheno-
typical staining against the classical leukocyte antigen CD45 to 
avoid the presence of contaminating leukocytes. Furthermore, 
we also found that MES cells were negative for vWF, a common 
marker used to detect endothelial cells. Interestingly, all MES 
were positive for CD68, a mature macrophage marker, although 
they were negative for CD14. Some of these markers were also 
analyzed by FACS (Figure 5C; Table 1).
IHC-positive staining for C1q in MPM tissues suggested that 
C1q may be produced locally. In this regard, C1q expression 
FigUre 3 | Histochemistry of hyaluronic acid on malignant pleural mesothelioma (MPM). Alcian blue staining highlights hyaluronic acid of epithelioid (a) and 
biphasic (B) malignant mesothelioma sections. Scale bars, 100 µm.
FigUre 4 | Interaction of C1q with hyaluronic acid. (a) C1q interaction with high-molecular-weight (HMW) hyaluronic acid (HA) and IgG (positive control) by  
ELISA. Microtiter wells coated with 50 µg/ml HMW HA or 10 µg/ml IgG were incubated with an increasing concentration of C1q; HA-bound C1q was revealed  
with anti-C1q antibodies. C1q bound HA with an affinity similar to IgG. The data are expressed as mean of three independent experiments in triplicates ± SEM.  
(B) Binding of C1q to different MW HA. Microtiter wells coated with 50 µg/ml HMW-HA (or 5, 20, 800, or 1,500 kDa HA) were incubated with increasing 
concentration of C1q and bound C1q was revealed with anti-C1q antibodies. No statistically significant difference was observed between the binding of C1q to low 
and high MW-HA was observed. The data are expressed as mean of three independent experiments carried out in triplicates ± SEM. (c–D) Evaluation of the ability 
of C1q bound to HA to activate the classical pathway of the complement system. Microtiter wells coated with 50 µg/ml HMW HA, or 10 µg/ml IgG were incubated 
with 20 and 50 µg/ml C1q. Pool of normal human sera (1:100) was added as a source of complement components and the deposition of C4 (c) and the formation 
of C9-neoantigen (C9 neo) (D) were revealed by using specific antibodies against C4 and C9 neoantigen (mAb aE11) by ELISA. The data are expressed as mean of 
three independent experiments carried out in triplicates ± SEM. (e) Dose response curve of the binding of ghA, ghB, and ghC to HMW HA. Microtiter wells were 
coated with 50 µg/ml HMW HA. The wells were then incubated with increasing amounts (0–10 µg/ml) of recombinant C1q globular head modules (ghA, ghB, ghC). 
The binding was revealed using anti-MBP antibody. The data are expressed as mean of three independent experiments done in triplicates ± SEM.
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FigUre 5 | Continued
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FigUre 5 | Continued   
Characterization of mesothelioma cells (MES). (a) Morphological features of the three different populations of MES (MES7, MES9, and MES12) isolated from 
malignant pleural mesothelioma (MPM) biopsies. Images were acquired by phase-contrast microscope, Leica original magnification: 200×. (B) Mesothelial cells were 
characterized by immunofluorescence for the expression of mesothelin, CK 8/18, vimentin, CD9, CD68 (green), and CD44 (red). Mesothelioma cells were grown to 
confluence in eight-chamber culture slides. After fixation and permeabilization, the cells were stained with mAb anti-human mesothelin, CK 8/18, vimentin, CD9, von 
Willebrand factor (vWF), CD68, and CD14, followed by anti-mouse-FITC F(ab)′ secondary antibodies or mAb anti-human CD45 and mAb anti-human CD44-PE 
conjugate. Nuclei were stained blue by DAPI: original magnification 200×. (c) The expression of mesothelin, CD68, CK8/18, calretinin, and vimentin was confirmed 
by FACS. The expression of these markers (green lines) was compared with appropriate control antibodies (black lines). (D) Binding of C1q to MES. Tumor cells 
grown to confluence on 96-well tissue culture plates were incubated with increasing concentrations of purified C1q for 1 h at room temperature and the bound C1q 
was revealed by ELISA. (e) The binding of 25 µg/ml C1q to MES was detected preincubating the cells with increasing concentration of hyaluronic acid (HA). Bound 
C1q was revealed by ELISA as described above. The data are presented as mean ± SEM of three separate experiments.
TaBle 1 | Marker expression evaluated by FACS analysis on cells isolated from 
five different epithelioid mesothelioma tumors.
Marker Mes7 Mes9 Mes12 Mes13 Mes14
Mesothelin + + + + +
Vimentin ++ ++ + + +
CK 8/18 ++ Nd + + +
Calretinin + Nd − + +
vWF − − − Nd −
CD68 ++ + + + +
CD45 − − − − −
CD44 ++ + Nd Nd ++
Data refer to cells between the third and the fifth passage in culture. ++ = positivity 
(>50%), + = positivity (<50%), − = negativity, Nd = not done.
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was evaluated at both mRNA and protein levels in healthy 
(Met5A) and tumor MES. We performed qPCR for three C1q 
chains (C1qA, C1qB, and C1qC); none were positive in five 
different cell populations (data not shown). Interestingly, C1q 
was found to bind strongly to the surface of MES (Figure 5D) 
and the extent of binding increased in the presence of HA being 
highest at the concentration of 50  µg/ml of HA (Figure  5E). 
To investigate the role of bound C1q on complement activation, 
we incubated C1q-bearing cells with AB+ human serum and 
analyzed the cells for the presence of C4 and C9 neoantigen on 
their surface. We failed to detect both complement components 
suggesting that binding of C1q to MES is not associated with 
complement activation.
c1q Promotes Mes adhesion  
and spreading
To evaluate the ability of C1q to interact with MES, we per-
formed a cell adhesion assay using immobilized C1q. MES 
(four different populations) and Met5A cells were labeled with 
the fluorescent probe FAST DiI and seeded on to immobilised 
C1q, HA or HA-bound-C1q; BSA was used as a negative 
control protein. Met5A cells were able to adhere to HA, and 
to a less extent, to C1q or HA-bound-C1q (Figure 6A). In con-
trast, MES showed greater adherence to HA; HA-bound-C1q 
was able to enhance MES adhesion considerably compared to 
HA alone (Figure 6B). All four MES populations showed the 
same behavior on HA-bound-C1q, although MES adhesion 
to C1q alone varied considerably between patients’ samples 
(Figure 7).
The analysis of the adherent MES by phase-contrast optical 
microscopy revealed that a high proportion of the cells seeded 
on to C1q or HA-bound-C1q were spread out, in contrast to 
the round morphology exhibited by those attached to HA or 
BSA (Figure 6C). In order to understand which module of the 
globular domain of C1q was mainly involved in MES adhesion, 
MES were stained with Fast DI and allowed to adhere to C1q, 
HA or recombinant globular heads (ghA, ghB, ghC) for 30 min. 
As shown in Figure 6D, the interaction of the cells with C1q 
seems to be mediated by ghC, and to a lesser extent, ghB. The 
cells did not seem to interact with ghA.
Since both HMW-HA and LMW-HA are present in the tumor 
microenvironment, we investigated the adhesion of MES to 
LMW-HA alone or in combination with C1q and we compared 
the results with the adhesion to HMW-HA with or without 
C1q. We did not observe any statistical difference between the 
MES adhesion to LMW or HMW-HA (Figure 6E).
c1q Promotes MPM Tumor Progression by 
Favoring Mes Proliferation and Migration
We investigated whether C1q might contribute to tumor growth 
by stimulating the proliferation of MES. Thus, MES were seeded 
on to solid phase C1q, HA, or HA-bound-C1q and the number 
of proliferating cells were evaluated using the Click-iT® EdU 
Microplate Assay. Our results indicated that HA-bound C1q 
was able to enhance the proliferation rate of MES (Figure 8A), 
compared to HA or C1q alone.
C1q-induced migration of labeled MES was examined by 
monitoring cell migration from the upper chamber through an 
insert coated with C1q, or HA-bound-C1q. C1q (60%) was found 
to be more effective than HA (~20%), in effecting migration 
(Figure 8B). In this assay, we did not observe a synergistic effect 
of the double matrix (HA-bound-C1q). In fact, the percentage 
of the cell migration due to HA + C1q was comparable to that 
observed with C1q alone.
The effect of C1q on the cell migration was also analyzed using 
a scratch wound healing assay, monitoring the mobilization of 
MES toward the scratched area for 18 h. As shown in Figure 9, 
MES stimulated by C1q started to enter the scratched area 
and migrated farther than cells exposed to HA after 18 h.
In order to investigate whether C1q was able to protect MES 
from apoptosis, serum-starved MES were allowed to adhere on to 
the wells, coated with HA or HA-bound-C1q, and then incubated 
with 500 µM H2O2 for 6 h. Subsequently, the activation of caspases 
3 and 7 was detected using a fluorogenic substrate. As shown in 
the graph in Figure 8C, the fluorogenic units of the MES on HA 
treated with H2O2 was double, compared to the untreated cells. 
FigUre 6 | Effect of C1q on mesothelioma cells (MES) adhesion. Mesothelial cells (Met5A) (a) and four different populations of MES (B) were labeled with the 
fluorescent dye FAST DiI and allowed to adhere to microtiter wells precoated with hyaluronic acid (HA), C1q, HA-bound-C1q, or bovine serum albumin (BSA).  
The data are expressed as mean of four independent experiments done in triplicates ± SEM. Cell adhesion was measured after 35 min. Results are expressed  
as percent of adhesion with reference to a standard curve established using an increasing number of labeled cells. (c) Morphological aspect of one representative 
primary cell line adhered to HA, C1q, HA-bound-C1q, or BSA. Images were acquired via phase-contrast microscopy, original magnification: 200×. (D) MES cells 
were labeled with the fluorescent dye FAST DiI and allowed to adhere to microtiter wells precoated with C1q, ghA, ghB, ghC, high molecular weight (HMW)-HA,  
or BSA. The data are expressed as mean of four independent experiments carried out in triplicates ± SEM. (e) MES were labeled with the fluorescent dye FAST DiI 
and allowed to adhere to microtiter wells precoated with HMW-HA, HMW-HA + C1q, low molecular weight (LMW)-HA, or LMW-HA + C1q. The data are expressed 
as mean of four independent experiments carried out in triplicates ± SEM.
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Surprisingly, MES adhering to C1q or HA-bound-C1q were not 
protected from apoptosis induced by oxidative stress (Figure 8C).
c1q enhances erK1/2, saPK/JnK, and 
p38 Phosphorylation in Mes cells
To further elucidate the mechanism of the cell activation, we 
analyzed the signaling pathways likely to be involved in tumor 
cell adhesion, migration and proliferation. We examined more 
specifically the activation of three members of the MAPK family, 
ERK1/2, SAPK/JNK, and P38 signaling molecules.
Serum-starved MES were allowed to adhere to wells coated 
with HA or HA-bound-C1q, for 5 or 20  min and the phos-
phorylation status of ERK1/2, SAPK/JNK, and P38 was 
evaluated by immunofluorescence using PathScan® Intracellular 
Signaling Array Kit (Cell Signaling Technology). As shown in 
Figures 10A–C, binding of MES to HA-bound-C1q resulted in 
the activation of all the signaling molecules, which was clearly 
seen at 20 min post stimulation for all pathways and the signal 
was significantly higher in the cells adhering to C1q bound to 
HA than in cells adherent to HA only. All three MAPK inhibitors 
tested in the adhesion assay proved to be effective in reducing 
significantly the cell adhesion to C1q bound to HA (Figure 10D).
DiscUssiOn
C1q is expressed in the stroma and vascular endothelium of a 
number of human malignant tumors, including adenocarcinomas 
of colon, lung, breast, and pancreas. In a murine model of 
melanoma, C1q was found to promote cancer cell adhesion, 
migration and proliferation (18). Thus, as a pro-tumorigenic 
FigUre 7 | Effects of C1q on mesothelioma cells (MES) adhesion. Four different populations of MES were labeled with the fluorescent dye FAST DiI and allowed to 
adhere to microtiter wells precoated with hyaluronic acid (HA), C1q, HA-bound-C1q, or bovine serum albumin (BSA). The results of each independent experiment, 
done in triplicates ± SEM are shown in order to highlight differential behavior of these cells. Cell adhesion was measured after 35 min. The results are expressed as 
percent of adhesion with reference to a standard curve established using an increasing number of labeled cells.
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soluble factor, C1q can promote tumor progression by facilitat-
ing cancer cell seeding and angiogenesis. Here, we investigated 
the presence and the role of C1q in MPM for a number of 
reasons. MPM is an aggressive neoplasm with a poor progno-
sis, because it is resistant to chemotherapy and radiotherapy. 
Therefore, studying the microenvironment of this tumor can 
help devise novel therapeutic strategies. In this study, we par-
ticularly focused our attention on the interaction between C1q 
and HA and its implication on adhesion and proliferation of 
MPM cells. Understanding this C1q-HA interaction is of great 
importance given a unique expression pattern of C1q in meso-
thelioma tissues and a great relevance of HA in the biology of 
the MPM.
IHC revealed that C1q was present in all the histological 
variants examined and it seemed primarily associated with 
monocytoid cells, indicating that these cells might be the main 
source of C1q locally. C1q was also diffusely present in the tumor 
stroma and associated with the cell membrane of tumor cells 
mainly of the epithelioid histotype. This pattern of expression is 
similar to that in other solid tumors (18) and is reminiscent of 
its distribution in human decidua (17). There were also areas in 
which C1q could be found associated with small vessels, raising 
the possibility that C1q might exhibit a proangiogenic activity in 
this context, similar to that in wound healing (23).
We first investigated the interaction of purified human C1q 
with HA since MPM is associated with a high level of production 
of HA (24). HA is highly expressed in MPM because it is respon-
sible for the lubrication of the pleural membranes and is secreted 
by the mesothelial cells (25). Here, we demonstrated that HA is 
abundantly present in MPM tissues, confirming an earlier study 
(22). HA has previously been shown to promote proliferation and 
migration of MPM cells through its interaction with hyaluronan 
receptor (26). We have previously shown that C1q can interact 
with HA (17). Here, we showed that C1q can bind to HMW-HA, 
and as expected, this binding does not induce complement acti-
vation. The interaction between C1 and HA has been studied 
in the past mainly considering its anti-complement activity (27, 
28). The interaction of C1q with synovial HA in rheumatoid 
arthritis has been previously reported (29); however, C1q binds 
synovial antibodies that are covalently coupled to HA. Heated 
and then lyophilized HA binds C1q (and a range of complement 
components) better that native HA, probably via polyanionic 
charges (30). A comparable binding activity was also observed 
for LMW-HA, whose local accumulation can be detected in 
the tumor microenvironment as a consequence of enhanced 
synthesis and turnover of HMW-HA. Since LMW-HA, but not 
HMW-HA, can stimulate a number of biological processes (31, 
32), it is likely that C1q can interfere with several functions 
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FigUre 8 | Effects of C1q on mesothelioma cells (MES) migration, 
proliferation, and apoptosis. (a–c) The experiments of cell migration, 
proliferation and apoptosis were performed as detailed in Section “Materials 
and Methods.” (a) MES proliferation. MES were seeded in wells precoated 
with hyaluronic acid (HA), C1q, HA-bound-C1q, or bovine serum albumin 
(BSA) and the number of proliferating cells was evaluated using the Click-iT® 
EdU Microplate Assay. (B) FAST DiI-labeled MES were allowed to migrate 
through a trans-well system polycarbonate membranes coated on the lower 
side with HA, HA-bound-C1q, C1q, or BSA. (c) Serum-starved MES cells 
were seeded in the wells precoated with HA, C1q, HA-bound-C1q, or BSA 
and incubated with H2O2. Apoptotic cells were ascertained by CellEvent™ 
Caspase-3/7 (Life Technologies). Data from at least five independent 
experiments are presented as mean ± SEM.
FigUre 9 | Effects of C1q on mesothelioma cells (MES) migration. For 
wound healing assays MES (2 × 105) were seeded in HESF + 0.1% BSA 
medium in 24-well plate and grown to 90–95% confluence. A scratch  
was placed in the middle of the well with a sterile 200 µl pipette tip. 
Subsequently, hyaluronic acid (HA) (50 µg/ml) or HA + C1q (20 µg/ml)  
were added to the wells. The invasion was evaluated in three separate 
experiments performed independently. The results of a representative 
experiment are shown. Images were acquired by phase-contrast 
microscope, Leica original magnification: 200×.
mediated by HA, such as angiogenesis and inflammation. To 
dissect the functional contribution of each chain within the 
heterotrimeric globular domain of C1q, we investigated the 
binding properties of the recombinant ghA, ghB, and ghC mod-
ules. Our results demonstrated that the ghA module was the best 
binder of HA.
The proadhesive properties of C1q that we demonstrated in vitro 
for murine melanoma cells (18) were also evident for MES. In this 
study, we made a significant step forward since we were able to test 
several populations of MES isolated directly from human patients. 
Here, we demonstrated that the effects mediated by C1q-bound-HA 
were different from that observed for HA or C1q alone in terms of 
the number of adhering cells as well as morphology indicating that 
the presence of C1q can considerably modify the tumor microen-
vironment. The proadhesion effect of C1q seems to be restricted to 
the cells isolated from primary tumors while Met5A cells, which 
are representative of non-tumor mesothelium, adhere better to HA, 
compared to the adhesion on C1q-bound-HA or C1q alone. These 
data indicate that C1q can exert differential effects depending on 
the cell types and probably expression of putative receptors. Among 
various C1q receptors gC1qR, also called HA-binding protein-1, is 
an interesting molecule for its ability to bind both the gC1q domain 
of C1q and HA. Furthermore, CD44, the main receptor for HA, 
has been described as a possible docking signaling molecule for 
the interaction with gC1q (33). The nature and consequences of 
interaction between these cellular receptors and C1q-bound-HA 
is currently under investigation. Another interesting observation 
is that the adhesion of MES to C1q is predominantly mediated via 
the ghC module. Since ghA is the preferential binder to HA, the 
gC1q domain can act as a bridging molecule for anchoring the 
tumor cells to the ECM. C1q-bound-HA was able to promote the 
growth and the migration of MES in vitro confirming our previous 
results (18), obtained with B16/F10 murine cells and C1q bound to 
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FigUre 10 | Phosphorylation of ERK1/2, SAPK/JUNK, and p38 in 
mesothelioma cells (MES). (a–c) MES were allowed to adhere to hyaluronic 
acid (HA) or HA-bound-C1q and the phosphorylation status of ERK1/2, 
SAPK/JUNK, and p38 was evaluated using total cell lysates with PathScan 
Antibody Array Kit (Cell Signaling), as described in the Section “Materials and 
Methods.” Data from at least three independent experiments are presented 
as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t-test).  
(D) Three different populations of MES were labeled with the fluorescent  
dye FAST DiI, preincubated for 30 min at 37°C with P38, ERK, or JNK 
inhibitors and then allowed to adhere to microtiter wells precoated with 
HA-bound-C1q. The data are expressed as mean of three independent 
experiments done in triplicates ± SEM. ***p < 0.001 vs. resting.
fibronectin. The finding that C1q alone did not exert a significant 
proliferating effect on MES seen previously on melanoma cells may 
be explained by differential response of cells derived from various 
tumors to C1q. It is also important to emphasize that this study 
was carried out on primary cells, which were freshly isolated from 
patients.
The activation of three members of the MAPK family, ERK1/2, 
SAPK/JNK, and p38 in this study is also consistent with the previ-
ously reported study (17).
That C1q can act as a tumor promoting factor in MPM 
confirms our recent data (18). In addition, Winslow et al. have 
observed that the three chains of C1q were highly expressed in the 
stroma of breast cancers with poor prognosis (34). On the con-
trary, Hong et al. reported that C1q is involved in the regulation 
of cancer cell survival and progression sustaining the activation 
of the tumor suppressor WW-domain containing oxidoreductase 
(WOX1). C1q downregulation enhanced prostate hyperplasia 
and tumorigenesis because of the lack of WOX1 activation (35). 
Recently, Kaur et al. have reported that C1q, via its gC1q domain, 
induced apoptosis in an ovarian cancer cell line SKOV3 via TNF-
α induced apoptosis pathway involving upregulation of Bax and 
Fas (36). These contrasting observations appear to suggest that 
the function of C1q in the biology of the tumor is complex and 
is strongly dependent on the microenvironment. Our hypothesis 
is that C1q can be locally produced by non-tumor cells and can 
interact differentially to the different ECM components present 
in the tumor microenvironment. The presence of C1q or C1 in 
soluble phase or bound to the ECM can provide different stimuli 
to the tumor cells present in the microenvironment.
In conclusion, C1q is abundantly present in mesothelioma 
tissue, interacts with HA, and interferes with adhesion, migra-
tion and proliferation of MES. The role of C1q is more complex 
than previously thought and is likely to be dependent on the 
tumor microenvironment. The availability of the recombinant 
globular domain of C1q may have implications for therapeutic 
approaches.
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